JPWO2022149609A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022149609A5 JPWO2022149609A5 JP2022574077A JP2022574077A JPWO2022149609A5 JP WO2022149609 A5 JPWO2022149609 A5 JP WO2022149609A5 JP 2022574077 A JP2022574077 A JP 2022574077A JP 2022574077 A JP2022574077 A JP 2022574077A JP WO2022149609 A5 JPWO2022149609 A5 JP WO2022149609A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- formula
- represented
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- 244000000010 microbial pathogen Species 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 230000002163 immunogen Effects 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 9
- 102000043129 MHC class I family Human genes 0.000 claims description 8
- 108091054437 MHC class I family Proteins 0.000 claims description 8
- 102000043131 MHC class II family Human genes 0.000 claims description 6
- 108091054438 MHC class II family Proteins 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 239000013638 trimer Substances 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 42
- 150000001413 amino acids Chemical class 0.000 claims 14
- 238000012986 modification Methods 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000036737 immune function Effects 0.000 claims 3
- 210000004877 mucosa Anatomy 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 210000001533 respiratory mucosa Anatomy 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000004913 activation Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 101800001092 Protein 3B Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 101800003106 VPg Proteins 0.000 description 2
- 101800001476 Viral genome-linked protein Proteins 0.000 description 2
- 101800001133 Viral protein genome-linked Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000024715 positive regulation of secretion Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021001522 | 2021-01-07 | ||
| PCT/JP2022/000327 WO2022149609A1 (ja) | 2021-01-07 | 2022-01-07 | Ｍｈｃ分子に適合する病原微生物由来のペプチドが担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン、並びに、免疫後の生理活性物質の分泌に関する情報の取得方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022149609A1 JPWO2022149609A1 (https=) | 2022-07-14 |
| JPWO2022149609A5 true JPWO2022149609A5 (https=) | 2025-01-15 |
Family
ID=82357968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574077A Pending JPWO2022149609A1 (https=) | 2021-01-07 | 2022-01-07 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20240316181A1 (https=) |
| JP (1) | JPWO2022149609A1 (https=) |
| WO (1) | WO2022149609A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2713879C (en) * | 2008-02-01 | 2020-01-07 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
| CA2765511C (en) * | 2009-06-16 | 2015-05-12 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| RU2577986C2 (ru) * | 2010-06-18 | 2016-03-20 | Дженентек, Инк. | Антитела против axl и способы их применения |
| CA2851917A1 (en) * | 2011-10-12 | 2013-04-18 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles as vaccines against infection with norovirus |
| JPWO2013085021A1 (ja) * | 2011-12-09 | 2015-04-27 | 株式会社林原 | 抗体産生増強用の組成物 |
| WO2018074558A1 (ja) * | 2016-10-23 | 2018-04-26 | デンカ株式会社 | 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン |
| US20220362370A1 (en) * | 2019-08-27 | 2022-11-17 | Tokyo Institute Of Technology | Composite protein monomer having non-structural protein of virus supported thereon, aggregate of composite protein monomer, and component vaccine comprising aggregate as active ingredient |
-
2022
- 2022-01-07 WO PCT/JP2022/000327 patent/WO2022149609A1/ja not_active Ceased
- 2022-01-07 US US18/271,078 patent/US20240316181A1/en active Pending
- 2022-01-07 JP JP2022574077A patent/JPWO2022149609A1/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2794637B1 (en) | Vesicular stomatitis virus for prime boost vaccines | |
| EP2953966B1 (en) | Induction of cross-reactive cellular response against rhinovirus antigens | |
| WO2024197167A1 (en) | A cold-adapted, live attenuated sars-cov-2 vaccine | |
| US20210393768A1 (en) | Compositions and methods for preventing and treating virus infection | |
| WO2022229817A1 (en) | Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use | |
| US9119803B2 (en) | Carious tooth vaccine and preparation method | |
| KR102709729B1 (ko) | 결핵의 예방 또는 치료용 약학적 조성물 | |
| CA2378437C (en) | Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines | |
| JPWO2022149609A5 (https=) | ||
| CN113939313B (zh) | 以肽核酸为基础的佐剂 | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| JP6401148B2 (ja) | 抗原および抗原の組み合わせ | |
| US11116837B2 (en) | Vaccine composition comprising hepatitis B virus like particle as adjuvant | |
| JP7651129B2 (ja) | ウイルスの非構造タンパク質が担持された複合タンパク質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン | |
| CN105801704B (zh) | 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用 | |
| CN114634579A (zh) | 一种抗新冠病毒基因工程疫苗 | |
| WO2021235503A1 (ja) | コロナウイルスの蛋白質が担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン | |
| JP6655736B2 (ja) | 呼吸器合胞体ウイルスワクチン | |
| KR20210002050A (ko) | 구제역 바이러스 백신 조성물 | |
| KR102872945B1 (ko) | 신규한 메르스 코로나바이러스 백신 조성물 및 이의 용도 | |
| US20240316181A1 (en) | Conjugated protein monomer carrying peptide derived from pathogenic microorganism compatible with mhc molecule, aggregate of said monomers, component vaccine containing said aggregate as active ingredient, and method for acquiring information on secretion of physiologically active substance after immunization | |
| US20240293532A1 (en) | Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use | |
| WO2025137448A1 (en) | T cell-based sars-cov-2 vaccine | |
| CN106362144B (zh) | 呼吸道合胞病毒疫苗 | |
| TW202525333A (zh) | 以經鼻投予所進行之細胞性免疫的誘導方法 |